NuPathe Jumps 10% on NDA Resubmission

Loading...
Loading...
Shares of NuPathe
PATH
were seeing increased strength during Tuesday's trading session after the company resubmitted its New Drug Application to the U.S. Food and Drug Administration. NuPathe stated it has resubmitted its New Drug Application (NDA) to the FDA for its migraine patch (NP101). NuPathe expects confirmation from the FDA regarding acceptance, resubmission classification and Prescription Drug User Fee Act (PDUFA) goal date within the next few weeks. The Company continues to expect a six-month review by FDA. "Resubmission of the NDA for our migraine patch is an important milestone for NuPathe," said Jane Hollingsworth, chief executive officer of NuPathe. "With the additional data and enhancements made to the patch, we have submitted a strong application and have an even more attractive commercial opportunity designed to address the needs of the nearly half of migraine patients who frequently experience both headache pain and migraine-related nausea," she continued. Tuesday, shares of NuPathe were trading up over 9 percent, at about $4.01 per share.
Posted In: NewsFDAIntraday UpdateMovers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...